11/29
09:23 pm
ocgn
How the Narrative Surrounding Ocugen Is Shifting After New Licensing and Analyst Developments [Yahoo! Finance]
Medium
Report
How the Narrative Surrounding Ocugen Is Shifting After New Licensing and Analyst Developments [Yahoo! Finance]
11/20
07:50 am
ocgn
Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference [Yahoo! Finance]
Low
Report
Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference [Yahoo! Finance]
11/20
07:02 am
ocgn
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
Medium
Report
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
11/15
08:21 pm
ocgn
How Recent Developments Are Rewriting the Story for Ocugen [Yahoo! Finance]
Medium
Report
How Recent Developments Are Rewriting the Story for Ocugen [Yahoo! Finance]
11/9
08:23 pm
ocgn
Ocugen Inc (OCGN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
Neutral
Report
Ocugen Inc (OCGN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
11/5
04:27 pm
ocgn
Ocugen outlines plans for three BLA filings in next three years amid global gene therapy expansion [Seeking Alpha]
Medium
Report
Ocugen outlines plans for three BLA filings in next three years amid global gene therapy expansion [Seeking Alpha]
11/5
06:30 am
ocgn
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
Low
Report
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
10/23
07:30 am
ocgn
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
Low
Report
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
10/18
04:14 am
ocgn
What Catalysts Could Shift the Ocugen Story After Recent Analyst Reactions and News? [Yahoo! Finance]
Neutral
Report
What Catalysts Could Shift the Ocugen Story After Recent Analyst Reactions and News? [Yahoo! Finance]
10/2
08:22 am
ocgn
Ocugen to Present at Industry and Investor Conferences in October 2025 [Yahoo! Finance]
Medium
Report
Ocugen to Present at Industry and Investor Conferences in October 2025 [Yahoo! Finance]
10/2
07:30 am
ocgn
Ocugen to Present at Industry and Investor Conferences in October 2025
Medium
Report
Ocugen to Present at Industry and Investor Conferences in October 2025
9/23
11:14 am
ocgn
Ocugen: A Retinal Disease Juggernaut In The Making [Seeking Alpha]
Medium
Report
Ocugen: A Retinal Disease Juggernaut In The Making [Seeking Alpha]
9/20
01:09 am
ocgn
Low
Report
9/19
08:07 am
ocgn
Ocugen (NASDAQ:OCGN) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
Low
Report
Ocugen (NASDAQ:OCGN) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
9/15
08:05 pm
ocgn
Why Ocugen Stock Zoomed 12% Higher Today [Yahoo! Finance]
Low
Report
Why Ocugen Stock Zoomed 12% Higher Today [Yahoo! Finance]
9/15
06:19 am
ocgn
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea [Yahoo! Finance]
Medium
Report
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea [Yahoo! Finance]
9/15
06:03 am
ocgn
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
Medium
Report
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea